US FDA Seeking New Orphan Products Office Director Amid Internal Moves
Executive Summary
OOPD’s deputy director has been named the acting head of the office responsible for orphan and rare pediatric disease designations.
You may also be interested in...
FDA’s New Orphan Products Director Brings Industry, Legal, Academic, Regulatory Background
Sandra Retzky worked at AstraZeneca and in Delaware's Medicaid fraud unit before joining the US FDA in 2016.
House Bills Would Close Orphan Exclusivity ‘Loophole’ And Thaw ‘Frozen’ Generic Labeling
US FDA-related legislation among the bills moving during the lame duck session of Congress.
Remdesivir’s Path To Orphan Designation Could Be Exploited By Others, Experts Warn
Congress should give FDA more flexibility to administer orphan designations, such as the ability to revoke designations later if the disease prevalence grows beyond the rare disease threshold.